Ramatroban

Ramatroban

Clinical data
Trade names	Baynas
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral (tablets)
ATC code	None
Legal status
Legal status	Rx-only (JP)
Identifiers
IUPAC name 3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
CAS Number	116649-85-5
PubChem CID	123879
IUPHAR/BPS	1910
ChemSpider	110413
UNII	P1ALI72U6C
KEGG	D01128
ChEMBL	CHEMBL361812
ECHA InfoCard	100.159.668
Chemical and physical data
Formula	C21H21FN2O4S
Molar mass	416.46 g/mol
3D model (Jmol)	Interactive image
SMILES C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
InChI InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N

Ramatroban (INN) is a thromboxane receptor antagonist.

It is also a DP₂ receptor antagonist.

It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma.

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the trade name Baynas.